Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D Ross CamidgeScott N Gettinger

Abstract

Purpose In patients with crizotinib-treated, anaplastic lymphoma kinase gene ( ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC), initial disease progression often occurs in the CNS. We evaluated brigatinib, a next-generation ALK inhibitor, in patients with ALK-positive NSCLC with brain metastases. Patients and Methods Patients with ALK-positive NSCLC received brigatinib (90 to 240 mg total daily) in a phase I/II trial (phI/II; ClinicalTrials.gov identifier: NCT01449461) and in the subsequent randomized phase II trial ALTA (ALK in Lung Cancer Trial of AP26113; ClinicalTrials.gov identifier: NCT02094573; patients in arm A received 90 mg once daily; patients in arm B received 180 mg once daily with 7-day lead-in at 90 mg). Primary end points (systemic objective response rates [ORRs]) were previously reported. Independent review committees assessed intracranial efficacy in patients with baseline brain metastases. Results Most patients with ALK-positive NSCLC had baseline brain metastases (50 of 79 [63%], phI/II; 80 of 112 [71%] and 73 of 110 [66%] in ALTA arms A and B, respectively), many of whom had no prior brain radiotherapy (23 of 50 [46%], phI/II; 32 of 80 [40%], ALTA arm A; 30 of 73 [41%], arm B). All patients,...Continue Reading

References

Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel B CostaKeith D Wilner
Jun 4, 2013·The New England Journal of Medicine·Alice T ShawPasi A Jänne
Dec 4, 2014·The New England Journal of Medicine·Benjamin J SolomonUNKNOWN PROFILE 1014 Investigators
Jan 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel B CostaLucio Crinò
Oct 5, 2015·The Lancet Oncology·Isabella ZhangBo Lu
Oct 7, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kimberly L JohungJoseph N Contessa
Jun 15, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chad G Rusthoven, Robert C Doebele
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sen ZhangVictor M Rivera
Nov 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Zabi Wardak, Hak Choy
Nov 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shirish M GadgeelSai-Hong Ignatius Ou
Dec 29, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason K MolitorisSteven J Feigenberg
May 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dong-Wan KimD Ross Camidge
Jun 7, 2017·The New England Journal of Medicine·Solange PetersUNKNOWN ALEX Trial Investigators

❮ Previous
Next ❯

Citations

Jun 26, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey R Zweig, Joel W Neal
Nov 6, 2018·Current Opinion in Oncology·Christoph Oliver RyserOliver Gautschi
May 18, 2019·American Society of Clinical Oncology Educational Book·Jordi Rodon AhnertJustin Gainor
Jul 23, 2019·Expert Opinion on Pharmacotherapy·G Hamilton, M J Hochmair
Nov 13, 2019·Journal of Oncology Practice·Vinicius Ernani, Thomas E Stinchcombe
Dec 7, 2019·Expert Review of Anticancer Therapy·Collin M Blakely, Jonathan W Riess
Dec 5, 2019·Organic & Biomolecular Chemistry·Chandrashekar Mudithanapelli, Mi-Hyun Kim
Aug 21, 2020·Clinical Pharmacokinetics·Neeraj GuptaKarthik Venkatakrishnan
Aug 12, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D Ross CamidgeSanjay Popat
Aug 16, 2018·Nature Reviews. Clinical Oncology·Gonzalo RecondoLuc Friboulet
Aug 2, 2018·Investigational New Drugs·Francesco FacchinettiMarcello Tiseo
Oct 4, 2018·The New England Journal of Medicine·D Ross CamidgeSanjay Popat
Nov 8, 2018·Experimental and Therapeutic Medicine·Linlin Zhang, Shuangquan Yu
Aug 7, 2020·PloS One·Marika L ForsytheZhaolin Xu
Oct 26, 2018·Frontiers in Oncology·Tyler P Robin, Chad G Rusthoven
May 29, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·E DudnikUNKNOWN Israel Lung Cancer Group
Jul 24, 2020·Oncology and Therapy·Hiu Ting ChanSiew-Kee Low
Mar 21, 2019·Expert Review of Respiratory Medicine·Jose M Pacheco, David R Camidge
May 8, 2019·Current Treatment Options in Oncology·Ugonma N Chukwueke, Priscilla K Brastianos
Aug 15, 2020·Neuro-oncology Advances·Joshua D PalmerDavid Roberge
Mar 20, 2019·Frontiers in Oncology·Vyshak Alva VenurPriscilla K Brastianos
Mar 27, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David F HeigenerMartin Reck
Nov 11, 2019·Trends in Pharmacological Sciences·Salvador GuardiolaErnest Giralt
Jan 27, 2021·Pharmaceuticals·Mei Elsayed, Petros Christopoulos
Nov 29, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Makoto NishioNobuyuki Yamamoto
Mar 2, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Lianxi SongYongchang Zhang
Sep 7, 2019·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Renaud DescourtChristos Chouaid
May 19, 2021·Nature Reviews. Drug Discovery·Philip CohenPasi A Jänne
Feb 3, 2020·Journal of the Neurological Sciences·Jigisha P ThakkarRimas V Lukas
Sep 17, 2021·Pharmacogenomics·Pasquale PisapiaGiancarlo Troncone
Sep 22, 2021·British Journal of Clinical Pharmacology·Simon E KoeleRob Ter Heine

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved